Bis(bipyridine)ruthenium(II) Ferrocenyl β‐Diketonate Complexes: Exhibiting Nanomolar Potency against Human Cancer Cell Lines

• Published in: Chemistry : a European journal Vol. 27; no. 11; pp. 3737 - 3744
• Main Authors: Allison, Matthew, Caramés‐Méndez, Pablo, Pask, Christopher M., Phillips, Roger M., Lord, Rianne M., McGowan, Patrick C.
• Format: Journal Article
• Language: English
• Published: WEINHEIM Wiley 19.02.2021; Wiley Subscription Services, Inc
• Subjects: Antineoplastic Agents - chemistry; Antineoplastic Agents - pharmacology; Bimetals; Bioassays; bioinorganic; Biotechnology; Cancer; Carboplatin; Cell Line, Tumor; Chemistry; Chemistry, Multidisciplinary; Cisplatin; Colon; Colorectal cancer; Comet Assay; Coordination Complexes - chemistry; Coordination Complexes - pharmacology; Coordination compounds; Cytotoxicity; Damage detection; DNA damage; hetero-bimetallic; Humans; Hypoxia; iron; Microbial Sensitivity Tests; Neoplasms - drug therapy; Neoplasms - pathology; Oxaliplatin; Pancreatic cancer; Pancreatic carcinoma; Physical Sciences; Platinum; Ruthenium; Ruthenium - chemistry; Ruthenium - pharmacology; Ruthenium compounds; Science & Technology; Toxicity; Tumor cell lines; bioinorganic; ruthenium; iron; cancer; hetero-bimetallic

The synthesis and characterization of new bis(bipyridine)ruthenium(II) ferrocenyl β‐diketonate complexes, [(bpy)2Ru(Fc‐acac)][PF6] (bpy=2,2′‐bipyridine; Fc‐acac=functionalized ferrocenyl β‐diketonate ligand) are reported. Alongside clinical platinum drugs, these bimetallic ruthenium‐iron complexes h...